Intrepida Bio, Inc. is a preclinical biotechnology company (founded 2019, headquartered in Encinitas / San Diego, CA) developing medicines that modulate the innate immune system to fight cancer and other diseases. Working with Biouniversa s.r.l., the company holds worldwide rights to develop proprietary monoclonal antibodies against the novel targets BAG3 and its receptor IFITM-2 — a signaling axis tumors hijack to build a growth-promoting, immune-evasive microenvironment (notably in pancreatic ductal adenocarcinoma, PDAC). Intrepida raised roughly $9.5M from Canaan, Sofinnova, Indaco Venture Partners and Vertis to fund IND-enabling studies of its lead oncology program. It was surfaced as a portfolio company of canaan-partners and added to the API Evangelist network as a stub. NOTE: this is a therapeutics/drug-discovery company with no public API, developer portal, or software product surface; its website (intrepidabio.com) no longer resolves and the entity appears dormant/defunct, so no API artifacts apply.
Intrepida Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Oncology, Immuno-Oncology, and Innate Immunity.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
aid: intrepedia-bio
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/intrepedia-bio.png
name: Intrepida Bio
description: 'Intrepida Bio, Inc. is a preclinical biotechnology company (founded 2019, headquartered in Encinitas / San Diego,
CA) developing medicines that modulate the innate immune system to fight cancer and other diseases. Working with Biouniversa
s.r.l., the company holds worldwide rights to develop proprietary monoclonal antibodies against the novel targets BAG3 and
its receptor IFITM-2 — a signaling axis tumors hijack to build a growth-promoting, immune-evasive microenvironment (notably
in pancreatic ductal adenocarcinoma, PDAC). Intrepida raised roughly $9.5M from Canaan, Sofinnova, Indaco Venture Partners
and Vertis to fund IND-enabling studies of its lead oncology program. It was surfaced as a portfolio company of canaan-partners
and added to the API Evangelist network as a stub. NOTE: this is a therapeutics/drug-discovery company with no public API,
developer portal, or software product surface; its website (intrepidabio.com) no longer resolves and the entity appears
dormant/defunct, so no API artifacts apply.'
url: https://raw.githubusercontent.com/api-evangelist/intrepedia-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-industry: Biotechnology
x-sub-industry: Immuno-oncology
x-founded: '2019'
x-headquarters: Encinitas, San Diego, CA, USA
x-founders:
- Joel F. Martin, Ph.D. (President & CEO)
- Olivier Laurent, Ph.D. (Chief Scientific Officer)
x-technology-targets:
- BAG3
- IFITM-2
x-investors:
- Canaan Partners
- Sofinnova Investments
- Indaco Venture Partners SGR
- Vertis
x-funding-raised: $9.5M
x-website: http://www.intrepidabio.com
x-website-status: unresolved (no DNS / registry "No match" as of 2026-07-19)
x-entity-status: dormant/defunct
x-has-api: false
x-enrichment-note: Enrichment pipeline ran 2026-07-19. No developer/API surface exists (biotech therapeutics company, website
offline), so no OpenAPI, MCP, well-known, packages, or security artifacts could be searched, generated, or derived. Only
the apis.yml identity pass was completed from public research (Canaan, Fierce Biotech, BioSpace, GlobeNewswire).
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Oncology
- Immuno-Oncology
- Innate Immunity
- Monoclonal Antibodies
- Cancer
- Drug Discovery
- Preclinical
- Therapeutics
tags_raw:
- Company
- Biotechnology
- Oncology
- Immuno-oncology
- Innate Immunity
- Monoclonal Antibodies
- Cancer
- Drug Discovery
- Preclinical
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →